Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2016

View Archived Issues

Servier gains worldwide license to Sorrento's anti-PD-1 antibody

Launch of the Human Cancer Models Initiative

EGCG with cognitive training shows beneficial effects for Down syndrome

Biocad's bispecific MAb shows promise for rheumatoid arthritis in preclinical studies

Amgen initiates first-in-human study of AMG-176 in multiple myeloma

Bayer and X-Chem expand global collaboration for drug discovery in areas of high unmet medical need

BerGenBio patents PKB gamma inhibitors

Forendo Pharma discloses 17beta-HSD1 inhibitors

Seres Therapeutics announces collaboration with Emulate

FDA lifts clinical hold on ROCKET study of JCAR-015

Jazz Pharmaceuticals gives update on acquisiton of Celator Pharmaceuticals

Emory University develops compounds for HBV infections

Pfizer presents prostanoid EP3 receptor antagonists

Seqirus ships seasonal influenza vaccines for the U.S. market

FDA approves Kovanaze nasal spray for dental anesthesia

Roivant Sciences and Plexcera announce formation of Enzyvant Sciences

Murine model of Zika virus disease developed at UTMBHealth

Positive topline results from phase II study of SAGE-547 in severe postpartum depression

Roche Diagnostics and Spanish partners to codevelop NNGS platform

In vitro and in vivo efficacy of novel antimicrobial agent with a dual mechanism of action

EMA committee recommends orphan drug designation for Akari's Coversin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...